MX378594B - Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos - Google Patents

Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos

Info

Publication number
MX378594B
MX378594B MX2018014130A MX2018014130A MX378594B MX 378594 B MX378594 B MX 378594B MX 2018014130 A MX2018014130 A MX 2018014130A MX 2018014130 A MX2018014130 A MX 2018014130A MX 378594 B MX378594 B MX 378594B
Authority
MX
Mexico
Prior art keywords
sup
epoxidation
intermediates
dienes
steroid
Prior art date
Application number
MX2018014130A
Other languages
English (en)
Spanish (es)
Other versions
MX2018014130A (es
Inventor
Alexander Charles Weymouth-Wilson
Laura Wallis
Timothy Evans
Zofia Komsta
Original Assignee
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nzp Uk Ltd filed Critical Nzp Uk Ltd
Publication of MX2018014130A publication Critical patent/MX2018014130A/es
Publication of MX378594B publication Critical patent/MX378594B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2018014130A 2016-05-18 2017-05-18 Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos MX378594B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1608776.9A GB201608776D0 (en) 2016-05-18 2016-05-18 Methods and compounds
PCT/GB2017/051389 WO2017199036A1 (en) 2016-05-18 2017-05-18 Process and intermediates for the 6,7-alpha-epoxidation of steroid 4,6-dienes

Publications (2)

Publication Number Publication Date
MX2018014130A MX2018014130A (es) 2019-04-29
MX378594B true MX378594B (es) 2025-03-11

Family

ID=56320628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014130A MX378594B (es) 2016-05-18 2017-05-18 Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos

Country Status (14)

Country Link
US (1) US10766921B2 (enExample)
EP (1) EP3458467B1 (enExample)
JP (1) JP7034094B2 (enExample)
KR (1) KR102489565B1 (enExample)
CN (1) CN109415404B (enExample)
AU (1) AU2017265445B2 (enExample)
CA (1) CA3024283C (enExample)
DK (1) DK3458467T3 (enExample)
EA (1) EA038224B1 (enExample)
ES (1) ES2841324T3 (enExample)
GB (1) GB201608776D0 (enExample)
MX (1) MX378594B (enExample)
PT (1) PT3458467T (enExample)
WO (1) WO2017199036A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN111560045A (zh) * 2020-06-23 2020-08-21 江苏佳尔科药业集团股份有限公司 一种以ba为原料合成石胆酸的方法
CN114957372B (zh) * 2021-12-07 2023-10-31 湖南醇康医药科技有限公司 10α-甲基-5,7-二烯甾体化合物和地屈孕酮的制备方法
CN114957371B (zh) * 2021-09-08 2023-10-31 湖南醇康医药科技有限公司 地屈孕酮及其中间体化合物的制备方法
GB202416085D0 (en) 2024-10-31 2024-12-18 Nzp Uk Ltd Reduction process

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
IT1088094B (it) 1976-10-14 1985-06-04 Hoffmann La Roche Derivati del pregnano
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
DE3902357A1 (de) 1989-01-27 1990-08-02 Hoechst Ag Verwendung von rheniumorganischen verbindungen zur oxidation von c-c-mehrfachbindungen, darauf basierende oxidationsverfahren und neue rheniumorganische verbindungen
US5166372A (en) 1992-02-07 1992-11-24 Arco Chemical Technology, L.P. Epoxidation process
ATE156158T1 (de) 1992-04-14 1997-08-15 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5723636A (en) 1996-04-12 1998-03-03 National Starch And Chemical Investment Holding Corporation Methyltrioxorhenium-urea hydrogen peroxide epoxidation of olefins
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
ITMI20030352A1 (it) 2003-02-27 2004-08-28 Chemi Spa Metodo per la sintesi di metiltriossorenio.
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
EP1775304A4 (en) 2004-07-13 2010-04-28 Mitsubishi Chem Corp PROCESS FOR THE PRODUCTION OF STEROIDS
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) * 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
DK2040713T3 (da) 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
US8796249B2 (en) 2008-07-30 2014-08-05 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
AU2009316484B2 (en) 2008-11-19 2015-04-16 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
JP2013500986A (ja) 2009-07-29 2013-01-10 ザ・ユニバーシティ・オブ・シカゴ 肝臓x受容体アゴニスト
ES2822375T3 (es) 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
NZ707389A (en) 2012-10-26 2018-08-31 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
WO2014085474A1 (en) 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
US20140206657A1 (en) 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
KR102526632B1 (ko) 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드
EA033427B1 (ru) * 2014-11-19 2019-10-31 Nzp Uk Ltd 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
JP6698085B2 (ja) 2014-11-19 2020-05-27 エヌゼットピー ユーケー リミテッド ステロイドFXRモジュレーター製造のための中間体としての6α−アルキル−6,7−ジオン−ステロイド
ES2748692T3 (es) 2014-11-19 2020-03-17 Nzp Uk Ltd Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
CN105348365A (zh) 2014-12-03 2016-02-24 四川百利药业有限责任公司 一种胆酸衍生物及其制备方法、药物组合物和用途
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608779D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds

Also Published As

Publication number Publication date
US10766921B2 (en) 2020-09-08
EA038224B1 (ru) 2021-07-27
KR20190007011A (ko) 2019-01-21
JP7034094B2 (ja) 2022-03-11
DK3458467T3 (da) 2020-12-14
AU2017265445B2 (en) 2020-12-03
KR102489565B1 (ko) 2023-01-17
CN109415404A (zh) 2019-03-01
CN109415404B (zh) 2022-08-26
EP3458467B1 (en) 2020-09-30
US20190309012A1 (en) 2019-10-10
PT3458467T (pt) 2021-01-05
GB201608776D0 (en) 2016-06-29
EP3458467A1 (en) 2019-03-27
MX2018014130A (es) 2019-04-29
ES2841324T3 (es) 2021-07-08
CA3024283C (en) 2024-07-02
WO2017199036A1 (en) 2017-11-23
AU2017265445A1 (en) 2018-11-15
EA201892516A1 (ru) 2019-05-31
BR112018073492A2 (pt) 2019-03-26
JP2019516729A (ja) 2019-06-20
CA3024283A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
MX377644B (es) 6.7.beta-epóxidos esteroideos como intermedios químicos.
JOP20210065A1 (ar) عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
PH12012500634A1 (en) Processes for preparing of glucopyranosyl -substituted benzyl -benzene derivatives
TW201129555A (en) Process for the manufacture of dabigatrane etexilate
EA201892516A1 (ru) Способ и интермедиаты для 6,7-альфа-эпоксидирования стероидных 4,6-диенов
MY167891A (en) Methods for the synthesis and purification of deoxycholic acid
MX2020006185A (es) Proceso para la preparacion de derivados de quinolina.
MX2020006306A (es) Método novedoso para producir 4,5-dihidroisoxazol 5,5-disustituido.
PH12019502865A1 (en) Method for preparing intermediate of 4-methoxypyrrole derivative
MX2017017022A (es) Metodo para la sintesis de derivados de rapamicina.
MX2019014323A (es) Metodo para preperar el intermediario de un derivado de 4-metoxipirrol.
MX2023011976A (es) Sintesis de compuestos analogos de rapamicina.
MX2020013827A (es) Proceso de preparacion de compuestos triciclicos.
MX384710B (es) Proceso para preparar 3-metilciclopentadecan-1,5-diona.
MX2016016730A (es) Metodo para preparar un producto intermedio de eribulina.
MX2022001495A (es) Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble.
JOP20180126A1 (ar) عمليات جديدة من أجل تحضير منشطات محلقة غوانيلات قابلة للذوبان
MX2020007364A (es) Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble.
MX2012006524A (es) Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindol.
MX2012007870A (es) Derivados de acido carboxilico que comprende un anillo de oxazolopirimidina 2, 5, 7-sustituido.
EP4282973A3 (en) Processes for the preparation of pyrimidinylcyclopentane compounds
CA2928305C (en) A crystalline anhydrous form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
NZ702684A (en) Hexadepsipeptide analogues as anticancer compounds
WO2012134102A3 (ko) 노보넨 디에스터 유도체, 이의 제조방법 및 이의 용도